



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



Ref: IMCL/CS/BM/2025

16th May, 2025

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai, Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 16th May, 2025

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Friday, 16th May, 2025 (i.e. today), inter-alia :

1. Approved the Audited Financial Statements for the year ended 31st March, 2025, and Audited Financial Results for the quarter/year ended 31st March, 2025, as recommended by the Audit Committee; and
2. Recommended a dividend @ 45% i.e. Rs. 4.50 per share for the financial year 2024-25.

Pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- i) Auditors' Report with unmodified opinion on the aforesaid Audited Financial Results (**Annexure A**);
- ii) Audited Financial Results for the quarter/year ended 31st March, 2025 (**Annexure B**);
- iii) Declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2025 (**Annexure C**).

We shall inform you in due course of time, the date on which the Company will hold its Annual General Meeting for the year ended 31st March, 2025, and the date on which dividend, if approved by the shareholders, will be paid or warrants thereof dispatched to the shareholders.

Further, Pursuant to SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated 19th October, 2023 ('SEBI Operational circular'), we hereby confirm that Indraprastha Medical Corporation Limited is not a Large Corporate (LC) as per the applicability criteria given in aforesaid circular. Relevant disclosure is given in the enclosed **Annexure D**.

The meeting of the Board of Directors commenced at 3.00 p.m. and concluded at 4.30 p.m.

This is for your information and record.

Thanking You,
Yours sincerely,
For Indraprastha Medical Corporation Limited

Priya Ranjan
AVP – Corporate Affairs & Legal
(Company Secretary & Compliance Officer)

Independent Auditor's Report

To the Board of Directors of Indraprastha Medical Corporation Limited

Report on the Audit of Financial Results**Opinion**

We have audited the Financial Results of **Indraprastha Medical Corporation Limited** ("the Company") for the year ended 31 March 2025 included in the accompanying Statement of 'Financial Results for the quarter and year ended 31 March 2025' ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 ("the Act") and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the Company for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit of Financial Results in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Financial Results.

Responsibilities of Management and Those Charged with Governance for the Financial Results

These Financial Results have been prepared on the basis of the annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of these Financial Results that give a true and fair view of the net profit and total comprehensive income and other financial information of the Company in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.



Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and Board of Directors.
- Conclude on the appropriateness of the management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

The Financial Results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **S.N. Dhawan & CO LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045

B. Sen.

Bhaskar Sen

Partner

Membership No.: 096985

UDIN: 25096985BMOPVW7208



Place: New Delhi

Date: 16 May 2025

INDRAPRASTHA MEDICAL CORPORATION LIMITED
Registered office : Sarita Vihar, Delhi Mathura Road, New Delhi - 110076
Corporate Identity Number : L24232DL1988PLC030958
Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629
E-mail: imclshares@apollohospitals.com, Website: delhi.apollohospitals.com



Statement of Audited Financial Results for the Quarter and Year ended 31st March, 2025

S. No.	Particulars	Quarter ended			Year ended	
		31.03.2025 (Refer Note 5)	31.12.2024 (Unaudited)	31.03.2024 (Refer Note 5)	31.03.2025 (Audited)	31.03.2024 (Audited)
1	Revenue from operations	333.75	324.93	314.73	1356.36	1244.70
2	Other income	6.35	5.13	4.89	22.65	16.89
3	Total income	340.10	330.06	319.62	1379.01	1261.59
4	Expenses					
	a) Cost of materials consumed	59.12	56.18	55.54	230.46	217.19
	b) Employee benefits expense	66.72	72.18	64.79	277.10	261.61
	c) Professional charges to doctors	87.31	86.04	80.12	355.18	311.79
	d) Finance costs	1.49	1.58	1.56	6.27	4.06
	e) Depreciation and amortisation expense	10.91	11.21	10.21	44.33	40.08
	f) Other expenses	59.28	58.34	65.84	249.35	260.75
	Total expenses	284.83	285.53	278.06	1162.69	1095.48
5	Profit before exceptional items and tax	55.27	44.53	41.56	216.32	166.11
6	Exceptional items	-	-	-	-	-
7	Profit before tax (PBT)	55.27	44.53	41.56	216.32	166.11
8	Tax expense					
	Current tax	17.10	11.87	9.17	59.38	43.03
	Deferred tax	(2.84)	(0.15)	1.22	(4.05)	(0.88)
9	Profit for the period after tax (PAT)	41.01	32.81	31.17	160.99	123.96
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss	(1.99)	(0.15)	1.28	(1.10)	2.47
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.50	0.04	(0.32)	0.28	(0.62)
	Total other comprehensive income (Net of tax expenses)	(1.49)	(0.11)	0.96	(0.82)	1.85
11	Total comprehensive income for the period	39.52	32.70	32.13	160.17	125.81
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year				505.01	386.09
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	4.47	3.58	3.40	17.56	13.52



Signature

Statement of Assets and Liabilities:		Amount (Rs. in crore)	
Particulars		As at	
		Audited	Audited
		31.03.2025	31.03.2024
A. ASSETS			
1 Non-current assets			
(a) Property, plant and equipment		296.43	311.99
(b) Right-of-use asset		31.04	33.90
(c) Capital work-in-progress		32.52	0.47
(d) Intangible assets		0.59	1.05
(e) Financial assets		57.12	62.68
(f) Other non-current assets		2.79	5.17
		420.49	415.26
2 Current assets			
(a) Inventories		6.99	7.53
(b) Financial assets			
(i) Trade receivables		75.45	58.40
(ii) Cash and cash equivalents		61.48	61.60
(iii) Bank balances other than (ii) above		260.27	162.83
(iv) Other financial assets		9.32	6.47
(c) Current tax assets (Net)		1.02	-
(d) Other current assets		16.60	11.15
		431.13	307.98
TOTAL OF ASSETS		851.62	723.24
B. EQUITY AND LIABILITIES			
1 Equity			
(a) Equity share capital		91.67	91.67
(b) Other equity		505.01	386.09
		596.68	477.76
Liabilities			
2 Non-current liabilities			
(a) Financial liabilities			
(i) Security deposits		0.83	0.88
(ii) Lease liabilities		30.54	32.27
(b) Provisions		29.47	27.19
(c) Deferred tax liabilities (Net)		15.39	19.72
		76.23	80.06
3 Current liabilities			
(a) Financial liabilities			
(i) Trade payables			
- Total outstanding dues of micro and small enterprises		3.68	0.97
- Total outstanding dues of creditors other than micro and small enterprises		118.86	131.92
(ii) Lease liabilities		2.22	1.68
(iii) Other financial liabilities		24.18	5.36
(b) Other current liabilities		21.03	22.75
(c) Provisions		8.74	2.16
(d) Current tax liabilities (Net)		-	0.58
		178.71	165.42
TOTAL OF EQUITY AND LIABILITIES		851.62	723.24



Signature

Statement of Cash Flows		Amount (Rs. in crore)	
Particulars		Year ended	
		31.03.2025 (Audited)	31.03.2024 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit before tax		216.32	166.11
<u>Add:</u>			
Depreciation and amortization expense		44.33	40.08
Interest expense		3.02	1.06
Loss on disposal of assets		0.52	1.17
<u>Deduct:</u>			
Interest income		22.65	16.89
Operating profit before working capital changes		241.54	191.53
<u>Adjustments for:</u>			
Trade and other receivables		(19.36)	13.87
Trade payables		(4.98)	40.67
Inventories		0.54	0.92
Cash generated from operations		217.74	246.99
<u>Deduct:</u>			
Interest paid		0.01	0.01
Income tax paid		60.98	46.83
Net cash generated from operating activities		156.75	200.15
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Property, plant & equipment and intangible assets (Net of sale)		(36.33)	(69.39)
Movement in other bank balances		(91.83)	(101.35)
Interest received		17.17	12.31
Net cash used in investing activities		(110.99)	(158.43)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Lease payments		(2.13)	(3.79)
Interest paid		(3.02)	(1.05)
Dividend paid		(40.73)	(27.54)
Net cash used in financing activities		(45.88)	(32.38)
Net increase / (decrease) in cash and cash equivalents		(0.12)	9.34
Opening cash and cash equivalents		61.60	52.26
Closing cash and cash equivalents		61.48	61.60
Components cash and cash equivalents			
Cash balance on hand		0.81	0.39
Balance with banks		60.67	61.21

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 16th May, 2025.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Board of Directors have recommended a dividend @ 45% (Rs. 4.50/- per share) for the financial year 2024-25. For previous year @ 45% (Rs. 4.50/- per share)
- The Company does not have any subsidiary/associate/joint venture company(ies), as on 31st March, 2025.
- The financial results for the three months ended 31st March, 2025 and 31st March, 2024 are the balancing figures between the audited figures for the respective years ended on those dates and the unaudited year to date figures for the nine months ending 31st December, 2024 and 31st December, 2023 respectively, which were subject to limited review.
- Previous year/period figures have been regrouped / rearranged wherever necessary.



Place : New Delhi

Date : 16th May, 2025

Shivakumar Pattabhiraman

Shivakumar Pattabhiraman

(Managing Director)

DIN: 08570283

**Indraprastha Medical Corporation Limited**

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>

Ref: IMCL/CS/BM/2025

16th May, 2025

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Declaration in terms of regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

Dear Sir,

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year 2024-25.

Thanking you,

Yours faithfully,

For Indraprastha Medical Corporation Limited

C. P. Tyagi
Chief Financial Officer



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



Annexure D

Particulars	Details
CIN	L24232DL1988PLC030958
Name of the Company	Indraprastha Medical Corporation Limited
Financial Year	From 1 st April, 2024 to 31 st March, 2025
Outstanding Qualified Borrowings at the start of the financial year i.e. as on 1 st April, 2024	NIL
Outstanding Qualified Borrowings at the end of the financial year i.e. as on 31 st March, 2025	NIL
Credit rating (highest in case of multiple ratings)	Not Applicable
Incremental borrowing done during the year (qualified borrowings)	NIL
Borrowings by way of issuance of debt securities during the year	NIL

For Indraprastha Medical Corporation Limited

C. P. Tyagi
Chief Financial Officer